Users Online: 338
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2020  |  Volume : 9  |  Issue : 1  |  Page : 6-12

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Date of Web Publication26-Dec-2019

Correspondence Address:
Dr. Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sajc.sajc_157_19

Rights and Permissions

How to cite this article:
Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K. An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome. South Asian J Cancer 2020;9:6-12

How to cite this URL:
Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K. An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome. South Asian J Cancer [serial online] 2020 [cited 2020 Sep 23];9:6-12. Available from:

Dear Editor,

Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated impressive efficacy in BRCA-mutated gynecological malignancies.[1],[2] Several lines of evidence now support that the DNA Damage repair (DDR)-deficient populations that benefit from PARPi go far beyond BRCA deficiency. Non-small cell lung cancer (NSCLC), the most common cause of death due to cancer worldwide, displays frequent DDR defects, the most frequent being ERCC1. This defect leads to platinum and PARPi sensitivity. Beyond ERCC1, DDR defects leading to platinum sensitivity widely overlap with those underlying PARPi sensitivity.[3],[4] Here, we report a case of 47-year-old doctor with no known comorbidites and family history of ovarian cancer in mother at 63 years and unknown primary squamous cell carcinoma with submandibular lymph node (LN) in sister at 42 years of age. He had hoarseness of voice in December 2016 which was evaluated to have squamous cell carcinoma lung with metastatic paratracheal and aortopulmonary LN after radical treatment with definitive radiotherapy of 59.6 Gy/28# with 6# weekly paclitaxel + carboplatin completed on January 26, 2017, followed by adjuvant 6 cycles of gemcitabine and cisplatin till May 20, 2017. He developed 1.5 cm × 1.2 cm enhancing lesion in the right posterior parietal lesion within 1 month of completion of therapy. He was treated with gamma knife (June 30, 2017) 25 gy for the brain metastasis which recurred with the size of 5 cm × 5.4 cm × 4 cm along with new cervical LN and soft tissue deposit in trapezius in January 2018. Excision of brain metastasis and whole-genome sequencing was performed on a biopsy from a metastasis and blood which revealed deleterious gene mutation in exon 2 of breast cancer 1 (BRCA1) (c.68_69delAG, p. Glu23ValfsTer17) confirming risk of hereditary breast and ovarian cancer syndrome (dated February 4, 2018 MedGenome Labs Private Ltd, Bengaluru, India and ACTREC Genetic Lab, Kharghar). He was then started on olaparib 300 mg twice daily from 10th February and response positron emission tomography-computed tomography suggest resolution in the lesion in R occipital lesion, mass deposit in trapezius and bilateral cervical Lymph node. On follow up he had sustained response till January 2019 when he developed oligometastatic right supraclavicular LN recurrence which was treated again with radical chemotherapy with cisplatin and definitive radiation to supraclavicular fossa with olaparib continued. As continued research into hazard ratio pathways and mutations within NSCLC emerge, new uses for PARP inhibition can be applied [Table 1]. These therapies have proven to be well tolerated on oral administration, making a compelling rationale for the continued study of these agents in lung cancer.[10]
Table 1: Trials demonstrating efficacy of Olaprib in solid tumors with breast cancer mutation

Click here to view

Financial support and sponsorship


aConflicts of interest

There are no conflicts of interest.

  References Top

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.  Back to cited text no. 1
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.  Back to cited text no. 2
O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 2014;4:42.  Back to cited text no. 3
Alexandrov LB, Stratton MR. Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014;24:52-60.  Back to cited text no. 4
Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Byers LA, Goldman RC, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients [abstract]. J Clin Oncol. 2014;32(5s). Abstract 7522.  Back to cited text no. 5
Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study. J Clin Oncol 2019;37:222-9.  Back to cited text no. 6
Molife LR, Roxburgh P, Wilson RH, Gupta A, Middleton MR, Michie TR, et al. A phase I study of oral rucaparib in combination with carboplatin.10.1200/jco.2013.31.15_suppl.2586 Journal of Clinical Oncology 2013;31:2586.  Back to cited text no. 7
Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. Aphase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:2344-51.  Back to cited text no. 8
Appleman LJ, Beumer JH, Jiang Y, Puhalla S, Lin Y, Ramalingam TK, et al. A phase I study of veliparib (ABT- 888) in combination with carboplatin and paclitaxel in advanced solid malignancies. 10.1200/jco.2012.30.15_suppl.3049 Journal of Clinical Oncology 2012;30:3049.  Back to cited text no. 9
A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients with Chemosensitive Advanced Non-Small Cell Lung Cancer. Available from: [Last accesed on 2019 Apr 24].  Back to cited text no. 10


  [Table 1]

This article has been cited by
1 Efficacy of weekly amrubicin for refractory or relapsed non-small cell lung cancer
Dong Dang,Chao Jiang,Ming-rui Xie
Medicine. 2020; 99(25): e20454
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Article Tables

 Article Access Statistics
    PDF Downloaded370    
    Comments [Add]    
    Cited by others 1    

Recommend this journal